Spots Global Cancer Trial Database for Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Official Title: Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Study ID: NCT05496036
Conditions
Interventions
Study Description
Brief Summary: The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Penn Medicine, Philadelphia, Pennsylvania, United States
Contact Details
Name: John Miura, MD
Affiliation: Penn Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
